Drug intelligence / Profile preview

TML-OTE-22

Development stage: Preclinical
Lead developer: Themis Medicare
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

TML-OTE-22 is a preclinical-stage anesthetic and hypnotic drug candidate developed by Themis Medicare. It utilizes a Novel Drug Delivery System (NDDS) designed to enhance the delivery and clinical profile of the active agent. The project is part of Themis Medicare's innovation pipeline, which focuses on value-added formulations and improved delivery mechanisms for established therapeutic classes. While the specific active ingredient has not been disclosed, the drug is intended for use in inducing anesthesia and hypnosis, likely targeting the central nervous system.

Beyond the preview

Go deeper on TML-OTE-22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TML-OTE-22.

Explore the full profile